

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the present application.

**Listing of Claims:**

1. (Currently Amended) A crystalline form (Form-C) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide having ~~a diffraction peak at a diffraction angle~~ ~~diffraction peaks at diffraction angles (2θ ± 0.2°)~~ of 11.4°, 13.0°, 14.4°, 15.2°, 16.4°, 17.0°, 19.1°, 19.8°, 20.4°, 20.9°, 22.6°, 24.0°, 24.5°, 25.0°, 25.6°, 26.3°, 26.8°, 28.8°, 31.6° and 32.7° in a powder X-ray diffraction.

2. (Canceled)

3. (Currently Amended) A crystalline form (Form-C) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide having ~~an absorption peak at a wavenumber~~ ~~absorption peaks at wavenumbers~~ of 3212 ± 1 cm<sup>-1</sup>, 2954 ± 1 cm<sup>-1</sup>, 2872 ± 1 cm<sup>-1</sup>, 2242 ± 1 cm<sup>-1</sup>, 2223 ± 1 cm<sup>-1</sup>, 1715 ± 1 cm<sup>-1</sup>, 1617 ± 1 cm<sup>-1</sup>, 1519 ± 1 cm<sup>-1</sup>, 1472 ± 1 cm<sup>-1</sup>, 1443 ± 1 cm<sup>-1</sup>, 1410 ± 1 cm<sup>-1</sup>, 1337 ± 1 cm<sup>-1</sup>, 1316 ± 1 cm<sup>-1</sup>, 1260 ± 1 cm<sup>-1</sup>, 1207 ± 1 cm<sup>-1</sup>, 1178 ± 1 cm<sup>-1</sup>, 1158 ± 1 cm<sup>-1</sup> and 1102 ± 1 cm<sup>-1</sup>, in an infrared absorption spectrum (KBr).

4. (Canceled)

5. (Currently Amended) A crystalline form ( $\text{Form-}\text{C}$ ) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide having a peak at a chemical shift peaks at chemical shifts of approximately 143.4 ppm, 137.7 ppm, 136.9 ppm, 134.2 ppm, 131.1 ppm, 128.5 ppm, 126.4 ppm, 125.8 ppm, 124.3 ppm, 120.0 ppm, 118.8 ppm, 115.8 ppm, 111.0 ppm, 84.5 ppm and 19.4 ppm in a  $^{13}\text{C}$  solid state NMR spectrum.

6. (Canceled)

7. (Withdrawn - Currently Amended) A process for preparing a crystalline form ( $\text{Form-}\text{C}$ ) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to claim 1, characterized in that comprising crystallizing N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide is crystallized using a simple solvent selected from the group consisting of n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, s-butyl alcohol, t-butyl alcohol and water, or a mixed solvent thereof as a crystallization solvent.

8. (Withdrawn) A process according to claim 7, wherein the crystallization solvent is a simple solvent of isopropyl alcohol or s-butyl alcohol, or a mixed solvent of s-butyl alcohol and water or a mixed solvent of isopropyl alcohol and water.

9. (Withdrawn) A process according to claim 7, wherein the crystallization solvent is a mixed solvent of s-butyl alcohol and water (volume ratio = 3:1-5:1) or a mixed solvent of isopropyl alcohol and water (volume ratio = 9:1-10:1).

10. (Withdrawn) A process according to claim 7, wherein the crystallization solvent is a mixed solvent of s-butyl alcohol and water (volume ratio = 3.9:1-4.1:1).

11. (Withdrawn) A process according to claim 7, wherein N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide is heated and dissolved in a solvent and then crystallized.

12. (Withdrawn) A process according to claim 7, wherein N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide is heated and dissolved in a solvent and then crystallized by gradual cooling.

13. (Withdrawn - Currently Amended) A process for preparing a crystalline form (Form-C) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to claim 1, characterized in that wherein N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide is heated at 80-130°C.

14. (Withdrawn - Currently Amended) A process for preparing a crystalline form (Form-C) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to claim 1, characterized in that wherein N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide is heated and stirred in water at 60-90°C.

15. (Withdrawn - Currently Amended) A process for preparing a crystalline form (Form-C) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to claim 1, characterized in that wherein a crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide hydrate [[are]] is heated at 80-130°C.

16. (Withdrawn - Currently Amended) A process for preparing a crystalline form (Form-C) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to claim 1, characterized in that wherein a crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide hydrate [[are]] is heated and stirred in water at 60-90°C.

17-22. (Cancelled)

23. (New) A crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide having the X-ray diffraction pattern substantially as depicted in Figure 3.

24. (New) A crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide having the  $^{13}\text{C}$  solid state NMR spectrum substantially as depicted in Figure 5.

25. (New) A crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide having the infrared absorption spectrum (KBr) substantially as depicted in Figure 7.

26. (New) A pharmaceutical composition comprising:

the crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to claim 1, and

a pharmaceutically acceptable carrier.

27. (New) A pharmaceutical composition comprising:

the crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to claim 3, and

a pharmaceutically acceptable carrier.

28. (New) A pharmaceutical composition comprising:

the crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to claim 5, and

a pharmaceutically acceptable carrier.